Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CIGB 247

Next Previous
Drug Profile

CIGB 247

Alternative Names: Antigen p64K hVEGFKDR adjuvant NAcGM3 VSSP; CIGB 247 V; CIGB-247; CIGB-247-V-vaccine; HeberSaVax vaccine; hVEGFKDR p64K antigen NAcGM3 VSSP adjuvant; hVEGFKDR p64K vaccine; hVEGFKDR- p64K antigen/adjuvant NAcGM3/VSSPs; p64K hVEGFKDR vaccine

Latest Information Update: 24 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Developer Center for Genetic Engineering and Biotechnology; Heber Biotec
  • Class Cancer vaccines; Eye disorder therapies
  • Mechanism of Action Immunostimulants; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Solid tumours
  • Discontinued Age-related macular degeneration

Most Recent Events

  • 24 Jul 2023 Discontinued - Preclinical for Age-related macular degeneration in Cuba (SC)
  • 28 Jun 2019 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Cuba (SC)
  • 05 Mar 2018 Efficacy and immunogenicity data from phase I/Ib trials presented at 16th International Congress on Targeted Anticancer Therapies

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top